RCKT / Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate

Rocket Pharmaceucticals (RCKT) soars 53.8% in a week on news of alignment with the FDA for the mid-stage study of RP-A501, an investigational gene the more_horizontal

Shares of Rocket Pharmaceuticals (NASDAQ: RCKT ) popped sharply higher on Wednesday, making it one of the top-trending tickers. Yesterday, the biotech more_horizontal

The company also announced a public stock offering that it said was worth $175 million. The clinical-stage biotech focuses on genetic therapies for ra more_horizontal

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) stock is soaring today, after the biotech name reached an "alignment" with the U.S. Food & Drug Administratio more_horizontal

Rocket Pharmaceuticals Inc (RCKT) shares surged 32% in pre-market trading on Wednesday after the biotechnology company developing gene therapy announc more_horizontal

Rocket Pharmaceuticals is developing gene therapies for rare diseases, with positive results and safety profiles from clinical trials. The company's f more_horizontal

The FDA grants fast track tag and orphan drug designation to Rocket's (RCKT) investigational gene therapy candidate, RP-A601, for cardiac indication. more_horizontal

Shares of Rocket Pharmaceuticals RCKT, +0.17% gained 2.3% premarket on Thursday after the late-stage biotech company said the U.S. Food and Drug Admin more_horizontal